GSA Capital Partners LLP Has $452,000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

GSA Capital Partners LLP reduced its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 64.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 54,350 shares of the company's stock after selling 100,410 shares during the quarter. GSA Capital Partners LLP's holdings in Amneal Pharmaceuticals were worth $452,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. Rothschild Investment LLC bought a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $26,000. DekaBank Deutsche Girozentrale bought a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $42,000. nVerses Capital LLC bought a new position in Amneal Pharmaceuticals in the 2nd quarter worth approximately $62,000. Bayesian Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals during the first quarter valued at approximately $65,000. Finally, Xponance Inc. bought a new stake in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $65,000. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Price Performance

AMRX stock traded down $0.12 during trading on Thursday, hitting $8.29. The company had a trading volume of 503,195 shares, compared to its average volume of 1,398,518. The company has a fifty day moving average price of $8.58 and a two-hundred day moving average price of $7.70. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $9.48.

Analyst Ratings Changes

AMRX has been the topic of a number of research reports. Truist Financial boosted their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. Barclays boosted their price objective on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 price objective on the stock in a research report on Friday, September 6th. Finally, StockNews.com raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $10.00.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the business's stock in a transaction on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares of the company's stock, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 26.56% of the company's stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.